Tomoko Yamagishi-Dressler Sells 4,536 Shares of Evolus, Inc. (NASDAQ:EOLS) Stock

Evolus, Inc. (NASDAQ:EOLS) CMO Tomoko Yamagishi-Dressler sold 4,536 shares of Evolus stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $60,147.36. Following the sale, the chief marketing officer now directly owns 95,671 shares in the company, valued at approximately $1,268,597.46. The trade was a 4.53 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Evolus Price Performance

Shares of NASDAQ EOLS opened at $13.03 on Friday. Evolus, Inc. has a twelve month low of $9.25 and a twelve month high of $17.82. The firm has a market cap of $828.54 million, a P/E ratio of -14.32 and a beta of 1.28. The company has a 50 day moving average of $13.42 and a 200 day moving average of $13.89. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $27.00 price objective on shares of Evolus in a research report on Wednesday, March 5th. Barclays boosted their price target on Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $22.00 price target on shares of Evolus in a research report on Wednesday, March 5th.

Hedge Funds Weigh In On Evolus

A number of hedge funds have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Evolus by 3.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,451 shares of the company’s stock worth $347,000 after acquiring an additional 1,094 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Evolus by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the company’s stock valued at $148,000 after buying an additional 1,291 shares during the last quarter. Rhumbline Advisers raised its stake in Evolus by 2.2% during the 4th quarter. Rhumbline Advisers now owns 80,149 shares of the company’s stock valued at $885,000 after buying an additional 1,762 shares during the last quarter. Tradition Wealth Management LLC raised its stake in Evolus by 18.2% during the 4th quarter. Tradition Wealth Management LLC now owns 13,000 shares of the company’s stock valued at $144,000 after buying an additional 2,000 shares during the last quarter. Finally, MetLife Investment Management LLC raised its stake in Evolus by 6.3% during the 4th quarter. MetLife Investment Management LLC now owns 34,272 shares of the company’s stock valued at $378,000 after buying an additional 2,044 shares during the last quarter. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.